Skip to main content
SpringerLink
Log in

Future directions for unsealed source radionuclide therapy for bone metastases

  • Editorial
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346:265–269.

    Article  Google Scholar 

  2. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993; 20:66–74.

    Article  CAS  PubMed  Google Scholar 

  3. Bonica JJ. Importance of effective pain control. Acta Anaesthesiol Scand Suppl 1987; 85:1–16.

    Article  CAS  PubMed  Google Scholar 

  4. Turner JH, Claringbold PG. A phase II study study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphate. Eur J Cancer 1999; 27:1084–1086.

    Article  Google Scholar 

  5. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357:336–341.

    Article  CAS  PubMed  Google Scholar 

  6. Burnet NG, Williams G, Howard N. Phosphorus-32 for intractable bony pain from carcinoma of the prostate. Clin Oncol (R Coll Radiol) 1990; 2:220–223.

    Article  CAS  Google Scholar 

  7. Ben Josef E, Maughan RL, Vasan S, Porter AT. A direct measurement of strontium-89 activity in bone metastases. Nucl Med Commun 1995; 16:452–456.

    Article  CAS  PubMed  Google Scholar 

  8. Ben Josef E, Lucas DR, Vasan S, Porter AT. Selective accumulation of strontium-89 in metastatic deposits in bone: radiohistological correlation. Nucl Med Commun 1995; 16:457–463.

    Article  CAS  PubMed  Google Scholar 

  9. Mertens WC, Stitt L, Porter AT. Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship? Am J Clin Oncol 1993; 16:238–242.

    Article  CAS  PubMed  Google Scholar 

  10. McCready VR, Dearnaley D, Al Deen A, Treleaven J. Ablation of secondary bone cancer from carcinoma of the prostate using high activities of Re-186 HEDP and peripheral stem cell support. Nuklearmedizin 1999:A35.

    Google Scholar 

  11. de Klerk JMH, Zonnenberg AB, van het Schip AD, et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21:1114–1120.

    Article  PubMed  Google Scholar 

  12. O’Sullivan J, McCready VR, Flux GD, Norman AR, Buffa FM, Chittenden S. High activity rhenium-186 HEDP with autologous peripheral blood refractory prostate cancer metastatic to bone. Br J Cancer 2002; 86:1715–1720.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20:189–196.

    Article  CAS  PubMed  Google Scholar 

  14. Franzius C, Bielack S, Flege S, Eckardt J, Sciuk J, Jurgens H, Schober G. High-activity samarium-153 EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin 2001; 40:215–220.

    CAS  PubMed  Google Scholar 

  15. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001; 42:1713–1721.

    CAS  PubMed  Google Scholar 

  16. Blake GM, Wood JF, Wood PJ, Zivanovic MA, Lewington VJ. 89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma. Eur J Nucl Med 1989; 15:49–54.

    CAS  PubMed  Google Scholar 

  17. McCready VR, O’Sullivan J, Dearnaley D, Treleaven J. Quantitative analysis of bone scans to determine if the dose to individual metastases from high activity Re 186 HEDP therapy depends upon the number of metastases. Radiology 2001; 221(P):344.

    Google Scholar 

  18. McCready VR, O’Sullivan J, Buffa F, et al. The relationship between skeletal metastatic load and therapeutic activity requirement in prostate cancer. Eur J Nucl Med 2001; 28:1054.

    Article  Google Scholar 

  19. McCready VR, Dearnaley D, Treleaven J. Relationship between size and response of prostatic skeletal metastases treated with high activities of Re-186 with peripheral blood stem cell support. Eur J Nucl Med 2000; 27:965.

    Article  Google Scholar 

  20. Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roentgenol 1984; 142:773–776.

    Article  CAS  Google Scholar 

  21. Berruti A, Cerutti S, Fasolis G, et al. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy. Gruppo Onco Urologico Piemontese (G.O.U.P). Anticancer Res 1997; 17:4697–4702.

    CAS  PubMed  Google Scholar 

  22. Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43:79–86.

    CAS  PubMed  Google Scholar 

  23. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357:336–341.

    Article  CAS  PubMed  Google Scholar 

  24. Schellhammer PF. Radical prostatectomy. Patterns of local failure and survival in 67 patients. Urology 1988; 31:191–197.

    Article  CAS  PubMed  Google Scholar 

  25. Wood DP Jr, Banks ER, Humphreys S, McRoberts JW, Rangnekar VM. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994; 74:2533–2540.

    Article  PubMed  Google Scholar 

  26. Partin AW, Steinberg GD, Pitcock RV, et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 1992; 70:161–168.

    Article  CAS  PubMed  Google Scholar 

  27. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337:295–300.

    Article  CAS  PubMed  Google Scholar 

  28. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomized double-blind cross over study to examine the efficacy of strontium-89 (89Sr) palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27:954–958.

    Article  CAS  PubMed  Google Scholar 

  29. Wheldon TE. Targeting radiation to tumours. Int J Radiat Biol 1994; 65:109–116.

    Article  CAS  PubMed  Google Scholar 

  30. Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998; 25:1362–1367.

    Article  CAS  PubMed  Google Scholar 

  31. Liepe KKJ, Hiscs R, Runge F, Knapp FF, Franke WG. Radiation dose of 188Re-HEDP in bone metastases. Eur J Nucl Med 2000; 27:266P.

    Google Scholar 

  32. Palmedo H, Guhlke S, Bender H, et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000; 27:123–130.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Marsden Hospital, Institute of Cancer Research Sutton Surrey, Surrey, SM2 5PT, UK

    V. R. McCready & J. M. O’Sullivan

Authors
  1. V. R. McCready
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. O’Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCready, V.R., O’Sullivan, J.M. Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med 29, 1271–1275 (2002). https://doi.org/10.1007/s00259-002-0914-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-002-0914-2

Search

Navigation